Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Britain Courts Anthropic Amid US Defense Department Dispute 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
CORALVILLE, Iowa, Aug. 03, 2017 -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that its president and chief executive officer, Travis C. Mickle, Ph.D., will present at the Canaccord Genuity 37th Annual Growth Conference being held August 9-10, 2017, at the InterContinental Boston Hotel.
Details of KemPharm's presentation are as follows:
| Date: | Thursday, August 10, 2017 | |||||
| Time: | 2:00 PM (ET) | |||||
| Location: | InterContinental Boston Hotel, 510 Atlantic Ave., Boston, MA 02210 | |||||
| Room: | The New York Room |
The presentation will be webcast and available on the Investor Relations section of the Company's website at http://investors.kempharm.com/.
About KemPharm
KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its LAT™ (Ligand Activated Therapy) platform technology. KemPharm utilizes its LAT™ platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of pain, ADHD and other central nervous system disorders. KemPharm’s co-lead clinical development candidates are KP415 and KP484, both based on a prodrug of methylphenidate, but with differing extended-release profiles for the treatment of ADHD, and KP201/IR, an acetaminophen-free formulation of the company’s immediate release abuse deterrent hydrocodone product candidate, KP201. For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com.
Investor Contacts: Jason Rando / Joshua Drumm, Ph.D. Tiberend Strategic Advisors, Inc. 212-375-2665 / 2664 [email protected] [email protected] Media Contact: Daniel L. Cohen Executive VP, Government and Public Relations KemPharm, Inc. 202-329-1825 [email protected]
